Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Abstract Introduction Access to first-line immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC) remains limited in many low- and middle-income countries. Consequently, tyrosine kinase inhibitors (TKIs) are still widely used. This study investigates the impact of f...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Saadet Sim, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Cengiz Karacin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Emre Yekedüz, Yüksel Ürün
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-07-01
Edice:	BMC Cancer
Témata:	Metastatic renal cell cancer Pazopanib Sunitinib Nivolumab
On-line přístup:	https://doi.org/10.1186/s12885-025-14654-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!